Palmitic acid-capped MIL-101-Al as a nano-adjuvant to amplify immune responses against Pseudomonas aeruginosa

• Published in: Nanoscale Vol. 16; no. 21; pp. 10306 - 10317
• Main Authors: Chen, Lingming, Liu, Shuai, Zhang, Yunting, Tang, Qiling, Quan, Chunyu, Wang, Jundan, Peng, Xinsheng, Zhong, Xiaofang
• Format: Journal Article
• Language: English
• Published: England Royal Society of Chemistry 30.05.2024
• Subjects: Adjuvants, Immunologic - chemistry; Adjuvants, Immunologic - pharmacology; Animals; Antigens; Biocompatibility; Capping; Drug resistance; Female; Immunology; Metal-organic frameworks; Metal-Organic Frameworks - chemistry; Metal-Organic Frameworks - pharmacology; Mice; Mice, Inbred BALB C; Nanoparticles - chemistry; Oligodeoxyribonucleotides - chemistry; Oligodeoxyribonucleotides - pharmacology; Palmitic acid; Palmitic Acid - chemistry; Pseudomonas aeruginosa; Pseudomonas aeruginosa - drug effects; Pseudomonas aeruginosa - immunology; Pseudomonas Infections - drug therapy; Pseudomonas Infections - immunology; Pseudomonas Infections - prevention & control
• ISSN: 2040-3364; 2040-3372
• DOI: 10.1039/d4nr01180e

As a highly contagious opportunistic pathogen, ( . ) is one of the main causes of healthcare-associated infections. The drug-resistant nature of . can render antibiotic treatments ineffective, leading to a high morbidity and mortality. Higher specificity and reduced toxicity are features of immunotherapy, which can generate robust immune responses and preserve long-term immunological memory to completely eradicate infections. In this study, we developed a type of vaccine based on a metal-organic framework. Specifically, MIL-101-Al nanoparticles were synthesized to encapsulate antigens derived from the bacterial lysate (BL) of PAO1, a drug-resistant . , and the adjuvant unmethylated cytosine-phosphate-guanine oligonucleotide (CpG), which were then modified with palmitic acid (PAA) to obtain MIL-BC@PAA. The stability and biocompatibility were significantly increased by capping with PAA. Moreover, MIL-BC@PAA showed significantly enhanced uptake by antigen presenting cells (APCs), and promoted their maturation. Importantly, immunity studies revealed the greatly elicited antigen-specific humoral and cellular responses, and a protection rate of about 70% was observed in . -challenged mice. Overall, these results demonstrate the promising potential of MIL-BC@PAA as an ideal nanovaccine for . vaccination.